FDA Clearance Tracker · K203833
Tacrolimus Assay Kit
Last checked: Nov 19, 2026Latest source record: Jan 27, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Jan 27, 2023
Substantially Equivalent
Time to decision
758 days
Received Dec 30, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K203833
- Device name
- Tacrolimus Assay Kit
- Applicant location
- Shanghai, CN
- Received
- Dec 30, 2020
- Decided
- Jan 27, 2023
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Enzyme Immunoassay, Tracrolimus (MLM)
- Device class
- Class II
- Regulation
- 21 CFR 862.1678
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MLM. The earliest in FDA's data is P970007, decided Aug 26, 1997.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K203833
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Shanghai Genext Medical Technology Co., Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.